The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia. - Wikidata - wikimedia - TriplyDB

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

http://www.wikidata.org/entity/Q38132301

about

Treatment of Gram-positive infections in critically ill patients Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity.Clinical management of Staphylococcus aureus bacteremia: a review.Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.Staphylococcus aureus bacteremia: targeting the source.Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections.CORR Insights®: Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.Empirical combination of a β-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy.Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37.Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.Ten old antibiotics that will never disappear.Synthesis and pharmacological evaluations of 4-hydroxycoumarin derivatives as a new class of anti-Staphylococcus aureus agents.Redeploying β-Lactams Against Staphylococcus aureus: Repurposing With a Purpose.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.Infective endocarditis.Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics

P2860

Q27015976-410644DE-9783-4A24-85AB-DFB29766A67F Q33700986-3F1F1FAE-3C32-41CE-8894-A9113398B0E1 Q34441035-1BDC2137-576F-4196-8E9E-17B59A389201 Q36026942-AC8E55D1-4F96-43A4-86D9-E4953E131F08 Q36576652-701202F0-C345-4F9D-BF06-57CBED6C7010 Q36836505-703760E8-AEB1-4712-A5E0-0214D7E85295 Q38258108-B5AD3D92-3E34-4C08-885C-AB6A85588155 Q39333835-E3EE89E0-5CA9-473B-A068-B848A236F350 Q40245967-92E08ECF-F6FE-4E3D-B693-7F594A360728 Q40375415-61A0130C-B8C1-4A9D-9CE5-DC92C34B82BE Q40655950-43AEC8BC-453B-457D-8EDE-0AC1A23560BD Q40813231-93F04E15-A106-4BF0-B7AA-18ABE5E9DCED Q40845477-D3174693-A091-480A-957B-8912502DC0EC Q41466409-83D8512E-6707-465E-945D-E1AF7A50B2CA Q41564963-ACFD50C7-DA2A-4F00-8952-7EBD217247FB Q45961041-D1DB487F-FD2F-4DE8-A526-1F6A134D4C40 Q47634145-46993167-D847-4278-8F3F-DE2539B6C7A3 Q48595162-F2CF6607-5551-44F2-8B72-676270B7AF64 Q52943386-A123722C-358B-4692-9262-8885EED37AD2 Q59135453-C0ECD33D-D954-4EEE-B50E-521D89D3D244

P2860

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

http://www.wikidata.org/entity/Q38132301

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

@en

type

label

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

@en

prefLabel

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

@en

P1433

Q38132301-FF7FE16B-CCB7-4590-9185-FF3F70FF95D1

P1476

Q38132301-327E7E7A-3774-42B3-9C6D-A23BD310A117

P2093

Q38132301-7E943000-021D-4AF2-8158-D46252E91DA1

Q38132301-9DBBA4D1-99D0-42C1-98F2-D2B466365C28

Q38132301-C8DECCCB-452D-4333-8581-018AC9EB58EA

P2860

Q38132301-013AB67B-B641-4927-A8EF-6B9333FD4BE8

Q38132301-0743D906-51FC-4632-8591-39D5B9677B99

Q38132301-0A8F744F-FA66-4567-BDCC-B52B1E66545B

Q38132301-0B92508D-42C6-4D4B-ADED-9733D56D7A77

Q38132301-10045472-487F-4E07-9DF2-854AF633FA4F

Q38132301-199DE513-0368-4F2D-A8C6-21A947DA437B

Q38132301-23F8C35A-DA2D-4104-952D-3755224340F3

Q38132301-256BAC0A-F068-4F60-BD5C-63C1CF10EA8C

Q38132301-39EE7C09-A3F8-44C0-871D-3498E283C17A

Q38132301-3BDB4986-1915-44F8-A306-07DE0211C1D7

P304

Q38132301-03F7DB90-CE74-4B6B-9C1E-C94C257638E2

P31

Q38132301-5AD212D6-3BB8-42E9-B4DF-8F0853EF9C4D

P356

Q38132301-13B41498-1989-4575-BAD0-F36E711111B4

P407

Q38132301-206EE1E4-8A02-449A-8C4A-C6B946C43981

P433

Q38132301-C8D0272E-4433-4911-A603-1E26DE073FC8

P478

Q38132301-1CF127E2-E64A-4377-85D9-09044091FEF4

P577

Q38132301-B36F4130-2586-4191-AFE6-7EB2ADED3CF3

P5875

Q38132301-21379FB6-66FC-4171-BF71-42105E6128AE

P698

Q38132301-28411E72-7B81-4965-A480-53063B6AA31A

P356

P1433

Clinical Infectious Diseases

P1476

The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.

@en

P2093

Keith A Rodvold

http://www.w3.org/2001/XMLSchema#string

Kevin W McConeghy

http://www.w3.org/2001/XMLSchema#string

Susan C Bleasdale

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data.

Identification and discrimination of Staphylococcus aureus strains using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

The risk of infection after nasal colonization with Staphylococcus aureus.

P304

1760-1765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIT560

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256200873

http://www.w3.org/2001/XMLSchema#string

P698

23985343

http://www.w3.org/2001/XMLSchema#string